Invesco Ltd. Blueprint Medicines Corp Transaction History

Invesco Ltd.

$516 Billion
Q4 2024

A detailed history of Invesco Ltd. transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Invesco Ltd. holds 960,437 shares of BPMC stock, worth $89.4 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

960,437

Previous 900,356 6.67%

Holding current value

$89.4 Million

Previous $83.2 Million 0.63%

% of portfolio

0.02%

Previous 0.02%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$82.48 - $101.39 $4.96 Million - $6.09 Million	60,081 Added 6.67%	960,437 $83.8 Million
Q3 2024 Nov 12, 2024	SELL	$84.1 - $120.5 $2.7 Million - $3.86 Million	-32,073 Reduced 3.44%	900,356 $83.2 Million
Q2 2024 Aug 13, 2024	BUY	$85.18 - $108.78 $10.5 Million - $13.4 Million	122,829 Added 15.17%	932,429 $100 Million
Q1 2024 May 14, 2024	BUY	$73.17 - $99.79 $28.7 Million - $39.1 Million	392,016 Added 93.88%	809,600 $76.8 Million
Q4 2023 Feb 12, 2024	BUY	$43.96 - $92.84 $15.2 Million - $32.1 Million	345,554 Added 479.74%	417,584 $38.5 Million
Q3 2023 Nov 13, 2023	BUY	$46.9 - $66.0 $211,096 - $297,066	4,501 Added 6.67%	72,030 $3.62 Million
Q2 2023 Aug 11, 2023	SELL	$42.2 - $66.37 $220,579 - $346,915	-5,227 Reduced 7.18%	67,529 $4.27 Million
Q1 2023 May 12, 2023	BUY	$37.97 - $50.0 $124,959 - $164,550	3,291 Added 4.74%	72,756 $3.27 Million
Q4 2022 Feb 13, 2023	BUY	$41.06 - $66.48 $136,565 - $221,112	3,326 Added 5.03%	69,465 $3.04 Million
Q3 2022 Nov 14, 2022	SELL	$49.93 - $77.7 $5.26 Million - $8.19 Million	-105,366 Reduced 61.44%	66,139 $4.36 Million
Q2 2022 Aug 15, 2022	BUY	$45.23 - $70.15 $4.33 Million - $6.71 Million	95,647 Added 126.09%	171,505 $8.66 Million
Q1 2022 May 16, 2022	SELL	$54.1 - $110.08 $1.15 Million - $2.34 Million	-21,243 Reduced 21.88%	75,858 $4.85 Million
Q4 2021 Feb 14, 2022	SELL	$94.25 - $115.99 $4.25 Million - $5.23 Million	-45,126 Reduced 31.73%	97,101 $10.4 Million
Q3 2021 Nov 15, 2021	SELL	$80.98 - $109.47 $1.47 Million - $1.98 Million	-18,105 Reduced 11.29%	142,227 $14.6 Million
Q2 2021 Aug 17, 2021	SELL	$82.78 - $101.0 $99.5 Million - $121 Million	-1,202,402 Reduced 88.23%	160,332 $14.1 Million
Q1 2021 May 17, 2021	BUY	$90.71 - $108.28 $1.13 Million - $1.35 Million	12,463 Added 0.92%	1,362,734 $132 Million
Q4 2020 Feb 16, 2021	BUY	$92.08 - $124.48 $9.19 Million - $12.4 Million	99,755 Added 7.98%	1,350,271 $151 Million
Q3 2020 Nov 16, 2020	SELL	$66.45 - $92.7 $191,442 - $267,068	-2,881 Reduced 0.23%	1,250,516 $116 Million
Q2 2020 Aug 14, 2020	SELL	$57.09 - $79.27 $33,968 - $47,165	-595 Reduced 0.05%	1,253,397 $97.8 Million
Q1 2020 May 15, 2020	SELL	$48.11 - $82.22 $13.7 Million - $23.3 Million	-283,839 Reduced 18.46%	1,253,992 $73.3 Million
Q4 2019 Feb 14, 2020	BUY	$66.73 - $82.59 $1.21 Million - $1.49 Million	18,096 Added 1.19%	1,537,831 $123 Million
Q3 2019 Nov 14, 2019	SELL	$72.9 - $101.41 $20.5 Million - $28.5 Million	-281,367 Reduced 15.62%	1,519,735 $112 Million
Q2 2019 Aug 14, 2019	BUY	$73.54 - $97.8 $132 Million - $175 Million	1,791,755 Added 19169.31%	1,801,102 $170 Million
Q1 2019 May 15, 2019	BUY	$48.7 - $86.6 $455,198 - $809,450	9,347 New	9,347 $748,000

Others Institutions Holding BPMC

# of Institutions

379

Shares Held

61.6M

Call Options Held

1.6M

Put Options Held

1.41M

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.56B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account